Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with Biochanin A (an Isoflavone) in rats

Phytotherapy Research

Volumn 26, Issue 2, 2012, Pages 303-307

  Singh, Sheelendra Pratap ^a,b   Wahajuddin, ^a   Raju, K S R ^a   Ali, Mushir M ^b   Kohli, Kanchan ^b   Jain, Girish Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

4 hydroxytamoxifen; biochanin A; CYP3A; P gp; pharmacokinetic; rats; tamoxifen

Indexed keywords

AFIMOXIFENE; BIOCHANIN A; CYTOCHROME P450 3A4; GLYCOPROTEIN P; TAMOXIFEN;

ADULT ANIMAL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERACTION; DRUG STRUCTURE; FEMALE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GENISTEIN; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

ANIMALIA; RATTUS;

EID: 84856252862     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3652     Document Type: Article

References (24)

1. An G, Morris ME,. 2010. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos 31: 340-350.
2. Chieli E, Romiti N, Cervelli F, Tongiani R,. 1995. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 57: 1741-1751.
3. Choi JS, Kang KW,. 2008. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch Pharm Res 31: 1631-1636.
4. Crewe HK, Ellis SW, Lennard MS, Tucker GT,. 1997. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53: 171-178. (Pubitemid 27013472)
5. Fakhoury M, Litalien C, Medard Y, et al,. 2005. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 33: 1603-1607. (Pubitemid 41539956)
6. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS,. 1995. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 133: 269-276.
7. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F,. 1991. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911-1919.
8. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN,. 1995. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529.
9. Jodoin J, Demeule M, Beliveau R,. 2002. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542: 149-159.
10. Kauffmann HM, Keppler D, Gant TW, Schrenk D,. 1998. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol 72: 763-768. (Pubitemid 29048919)
11. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D,. 1993. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656. (Pubitemid 23221760)
12. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J,. 2006. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 95: 1984-1993. (Pubitemid 44433029)
13. Piao Y, Shin SC, Choi JS,. 2008. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 29: 245-249. (Pubitemid 351802847)
14. Powles TJ,. 1992. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340: 1145-1147.
15. Rao US, Fine RL, Scarborough GA,. 1994. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48: 287-292.
16. Shin SC, Choi JS, Li X,. 2006. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313: 144-149.
17. Stone R., 1992. NIH fends off critics of tamoxifen study. Science 258: 734.
18. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T,. 2003. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2: 105-112.
19. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW,. 2001. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol 14: 1596-1603. (Pubitemid 34016623)
20. Wang X, Wolkoff AW, Morris ME,. 2005. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33: 1666-1672. (Pubitemid 41539965)
21. Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH,. 2007. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 55: 7620-7625. (Pubitemid 47492324)
22. Zhang S, Morris ME,. 2003a. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304: 1258-1267. (Pubitemid 36254439)
23. Zhang S, Morris ME,. 2003b. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20: 1184-1191. (Pubitemid 36951843)
24. Zhang S, Yang X, Morris ME,. 2004. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65: 1208-1216. (Pubitemid 38543491)